Mutagenic effects of some anticancer antibiotics

Evaluation of the genotoxic potential of selected anti-AIDS treatment drugs at clinical doses in vivo in mice

Six anti-AIDS drugs were assessed for in vivo genotoxicity and cytotoxicity at human clinical doses with the mouse bone marrow micronucleus assay. These included four dideoxynucleosides (azidothymidine, dideoxycytidine, dideoxyadenosine, and dideoxyinosine), an anthracycline antibiotic (doxorubicin), and a chelating agent (D-penicillamine). Cytological analysis of the mouse bone marrow cells revealed: (i) The dideoxynucleosides and D-penicillamine failed to induce significant number of micronuclei, and except for one of the five doses of dideoxyinosine, none of the dideoxynucleosides were cytotoxic at the doses tested. (ii) Doxorubicin induced micronuclei in a dose-dependent manner which was statistically significant at 4-times the clinical dose but was not cytotoxic at any of the doses tested.

Comparative studies on genotoxic and carcinogenic effects of different cytostatic protocols. I. In vivo cytogenetic analyses in CBA mice

In vivo rodent cytogenetics may provide an important basis for an animal model for the assessment of the carcinogenic potential of antitumor drugs in man. In this paper, genotoxic alterations (i.e. sister chromatid exchanges and micronuclei) caused by different cytostatic protocols in CBA/Ca mice are described. The strongest sister chromatid exchange inducing effects were shown by the ABVD (doxorubicin-dacarbazine-bleomycinvinblastine) group and combinations containing cyclophosphamide. Compounds which affect the mitotic spindle induced only micronuclei, but not sister chromatid exchanges.

Persistence of drug-induced chromosome aberrations in peripheral blood lymphocytes of the rat

We have studied the persistence of pre-clastogenic lesions, detected as induced chromosomal aberrations, in rat peripheral lymphocytes at various time intervals after acute treatment with 3 different antineoplastic drugs: cyclophosphamide (CPA), 5-fluorouracil (5-FU) and adriamycin (AM). Single i.p. doses were administered to groups of rats and heart blood samples from each group were taken after 3, 12, 24 or 48 h or weekly up to 20 weeks later. The cytogenetic analysis was performed on lymphocytes cultured for 33 h after sampling. The results for CPA exposure (10 mg/kg) show that the yield of chromosome aberrations is maximal 3 h after the treatment (20 times the control level). For up to 8 weeks the values remain about 6 times the baseline; afterwards a decrease is observed and the control level is reached after 20 weeks. For 5-FU (50 mg/kg) a remarkable increase (13-fold) in chromosomal damage is observed at the first sampling time. Within 48 h the effect is drastically reduced but persistent (3 times the control level), and the level returns to spontaneous values 1 week later. AM treatment (2 mg/kg) induced an increase of about 8 times the control level at 3 h post exposure. The clastogenic effects remained at a detectable level for 1 week (about 6 times the control level at all sampling times); 2 weeks after the treatment the control level was found. A parallel analysis was performed on bone marrow cells. In this tissue the clastogenic effects of the treatments were maximal, as in lymphocytes, at the first sampling time (20-25 times the control level) and were no longer detectable within 72 h after exposure, irrespective of the administered drug.

Daunorubicin-induced mammary tumors in the rat

Eleven of 24 female Sprague-Dawley rats given a single i.v. injection of daunorubicin (10 mg/kg) developed mammary tumors within 8 months after the injection. Four of 12 rats given an intramammary injection of daunorubicin (4 or 8 micrograms) developed five mammary tumors in the injected area within 6.5 months of injection. Tissue distribution studies using tritiated daunorubicin revealed that the liver, kidney, lung, heart, and intestine had higher daunorubicin concentrations than mammary tissue during the first 24 h after i.v. injection. However, depletion of the drug from the internal organs was more rapid than from mammary tissue. Differences in ability to metabolize daunorubicin were compared in homogenates of isolated mammary epithelial cells and hepatocytes by high-performance liquid chromatography: after 90 min, hepatocytes metabolized about 70% of daunorubicin, whereas mammary epithelial cells did not metabolize the drug. Tritiated daunorubicin injected directly into rat mammary gland showed no metabolism in 24 h, and the drug did not get into the circulation. These results suggest that retention of daunorubicin because of the inability of mammary tissue to metabolize the drug is a cause of drug-induced mammary tumors in female Sprague-Dawley rats.

DNA repair replication, DNA breaks and sister-chromatid exchange in human cells treated with adriamycin in vitro

The effects of adriamycin (AM) on DNA repair replication, the frequency of sister-chromatid exchange (SCE), the rate of cell proliferation and the frequency of DNA strand breaks were studied in human cells in vitro. No repair replication was observed in lymphocytes exposed to AM in concentrations up to 10(-3) moles/l. DNA repair replication induced by UV and alkylating agents was not affected by a concentration of AM that completely inhibited cell proliferation (10(-6) moles/l). Fibroblasts exposed to AM at 10(-4) moles/l in the presence of hydroxyurea showed an increase of strand breaks and cross-links in DNA. When AM was added to UV-irradiated fibroblasts, there was an increase of DNA strand breaks in addition to the breaks caused by UV alone. Similar effects were observed in lymphocytes. A dose-dependent increase of SCE was observed in lymphocytes exposed to low concentrations of AM (less than 10(-7) moles/l). At higher concentrations the increase of SCE levelled off, and cell proliferation became severely inhibited. There was no evidence of removal of SCE-inducing damage in cells exposed to AM during G0 or G1. The level of SCE induced in the third cell cycle after treatment with AM was not different from that induced during the first two cell cycles. These results suggest that the various genotoxic and cytotoxic effects of AM are caused by different types of cellular damage. Moreover, AM-induced DNA damage persists for several cell cycles in human cells in vitro and seems to be resistant to repair activity.

Immunological studies of PK and PFK deficiencies induced by chemotherapy

Pyruvate kinase (PK) and phosphofructokinase (PFK) erythrocyte deficiencies induced by chemotherapy were studied in 6 patients. From immunological tests it may be assumed that the PK and PFK deficiencies were due to different direct mechanisms: a disturbance of the synthesis of one of the PFK subunit; mutation(s) in the structural gene of PK which result in the synthesis of mutant proteins. Several molecular mechanisms are probably at the origin of all the disturbances induced by chemotherapy in the red blood cells. The study of these alterations which mimic those detected in preleukaemic and leukaemic states, provides information on the molecular events in the possible production of chemo-induced cancers.

The mutagenic effect of cis-diamminedichloroplatinum (II) and its degradation products in the Ames microbial assay

cis-Diamminedichloroplatinum (II), an antitumor compound which exhibits mutagenic activity, and its degradation products platin B salt, magnus red, and magnus red anion salt were tested in the Ames microbial mutagenicity assay. The purpose of this investigation was to determine if the positive mutagenic response of the platinum compound could be due to, or enhanced by, the presence of degradation products. Results indicate that platinum degradation complexes are weak mutagens which are capable of inducing both base pair and frameshift-type mutations.